ArticleBioinformatics (Oxford, England)2020
Breeze: an integrated quality control and data analysis application for high-throughput drug screening.
Article in Bioinformatics (Oxford, England), 2020. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 66 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
66 citing papers in PubMed.
- Functional profiling of ovarian cancer models reveals Bcl-xL/NOTCH targeting to overcome resistance.NPJ precision oncology · 2026Article
- Patient cell drug profiling identifies p53-linked vulnerabilities in refractory lymphoid malignancies.NPJ precision oncology · 2026Article
- Midostaurin response in AML is shaped by a progenitor-like cell state selectively targeted by SMAC mimetics.NPJ precision oncology · 2026Article
- Novel therapeutic strategies for ccRCC through integration of systemic drug combinations and oncolytic adenovirus immunotherapy.Frontiers in immunology · 2026Article
- Combination of vemurafenib, pleconaril, and AG7404 attenuates enterovirus replicationNAR molecular medicine · 2026Article
- Navitoclax acts synergistically with irradiation to induce apoptosis in preclinical models of H3K27M-altered diffuse midline glioma.Scientific reports · 2025Article
- Unbiased combination screening on repurposed drugs reveals synergistic potential of copanlisib and cerivastatin against chemoresistant high-grade serous ovarian cancer.Journal of ovarian research · 2025Article
- Comparative preclinical drug response analyses of T-prolymphocytic leukemia reveal no differences between known gene expression subgroups.Biology direct · 2025Article
- Evaluation and modification of tumor cell isolation techniques from malignant effusions for rapid drug sensitivity testing.Molecular oncology · 2025Article
- Systematic profiling of cancer-fibroblast interactions reveals drug combinations in ovarian cancer.Molecular oncology · 2025Article
- Functional screening identifies kinesin spindle protein inhibitor filanesib as a potential treatment option for hepatoblastoma.NPJ precision oncology · 2025Article
- Article
- Exploiting NRF2-ARE pathway activation in papillary renal cell carcinoma.International journal of cancer · 2025Article
- JAK inhibitors remove innate immune barriers facilitating viral propagation.NAR molecular medicine · 2025Article
- The first-in-Africa ex vivo drug sensitivity testing platform identifies novel drug combinations for South African leukaemia patient cohort.Scientific reports · 2025Article
- A multiplex single-cell RNA-Seq pharmacotranscriptomics pipeline for drug discovery.Nature chemical biology · 2025Article
- Evaluating feature extraction in ovarian cancer cell line co-cultures using deep neural networks.Communications biology · 2025Article
- Functional-proteomics-based investigation of the cellular response to farnesyltransferase inhibition in lung cancer.iScience · 2025Article
- Synergistic combination of orally available safe-in-man pleconaril, AG7404, and mindeudesivir inhibits enterovirus infections in human cell and organoid cultures.Cellular and molecular life sciences : CMLS · 2025Article
- Molecular and functional profiling of primary normal ovarian cells defines insights into cancer development and drug responses.Molecular therapy. Oncology · 2024Article
6 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
12 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
summaryHigh-throughput screening (HTS) enables systematic testing of thousands of chemical compounds for potential use as investigational and therapeutic agents. HTS experiments are often conducted in multi-well plates that inherently bear technical and experimental sources of error. Thus, HTS data processing requires the use of robust quality control procedures before analysis and interpretation. Here, we have implemented an open-source analysis application, Breeze, an integrated quality control and data analysis application for HTS data. Furthermore, Breeze enables a reliable way to identify individual drug sensitivity and resistance patterns in cell lines or patient-derived samples for functional precision medicine applications. The Breeze application provides a complete solution for data quality assessment, dose-response curve fitting and quantification of the drug responses along with interactive visualization of the results. AVAILABILITY AND IMPLEMENTATION: The Breeze application with video tutorial and technical documentation is accessible at https://breeze.fimm.fi; the R source code is publicly available at https://github.com/potdarswapnil/Breeze under GNU General Public License v3.0. CONTACT: swapnil.potdar@helsinki.fi. SUPPLEMENTARY INFORMATION: Supplementary data are available at Bioinformatics online.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.